AU
INDV icon

AlphaGrep UK’s Indivior Pharmaceuticals INDV Stock Holding History

AlphaGrep UK’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Buy
+6,320
New +$229K 0.08% 566

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaGrep UK's INDV Position: Q2 2026 in Review

AlphaGrep UK opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 6,320 shares worth $259K. The stake represents 0.08% of the portfolio and ranks #566 among its holdings.

315 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • AlphaGrep UK held 6,320 shares of Indivior Pharmaceuticals worth $259K as of Q2 2026.
  • Indivior Pharmaceuticals was a new AlphaGrep UK position in Q2 2026.
  • Indivior Pharmaceuticals made up 0.08% of AlphaGrep UK's portfolio in Q2 2026, its #566 holding.
  • 315 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.